Formulation: Ig fraction
Reacts in: Human
No Available References
- Lilly Halts IDENTITY Trials as Patients Worsen on Secretase Inhibitor
- Research Brief: More Evidence That CSF Aβ Changes Precede AD
- Draft Framework for National AD Plan Released
- NAPA and the National Plan—Is Your Input Getting Through?
- Induced Neurons From AD Patients Hint at Disease Mechanisms
- Astrocyte Imaging Supports Early Inflammation in the AD Brain
- Intracellular Aβ Causes Neurodegeneration in Mice
- Mice Tell Tale of Tau Transmission, Alzheimer’s Progression
- Beyond Aβ: Other APP Fragments Affect Neuron Health and Disease
- San Francisco: Tweaking Brain ApoE Reduces Aβ, Symptoms
- HHS Seeks Input on Draft National Plan
- Would Congress Please SPRINT Toward Cures?
- Miami: Amyloid PET in the Clinic: What Are the Issues?
- Miami: Longitudinal Amyloid PET Data Start Converging
- Research Brief: Expanded Registry to Grow DIAN Population
- Antioxidants No Help for Alzheimer’s, Biomarker Trial Says
- Keystone: Symposium Emphasizes Key Aspects of ApoE Biology
- FDA Approves Amyvid for Clinical Use
- News Brief: Sebelius Gives Report on U.S. Alzheimer's Plan
- Synthetic Synuclein Corrupts Native Along Mouse Brain Networks
- Imaging Inflammation: Can Glial PET Tracers Make a Mark?
- DIAN Grows, Gets Ready for Therapeutic Trials
- Q&A With Ryan Watts, Genentech Lead Scientist on API Trial
- ApoE4 Makes Blood Vessels Leak, Could Kick Off Brain Damage
- Coming to a City Near You: Tracer to Picture Brain Amyloid
- Amyloid Imaging Task Force to Work Out Technology's Use
- Aβ Sufficient for Seeding—But Is It a Prion?
- Communication Breakdown: Multiple Networks Decline in AD Brains
- Protective APP Mutation Found—Supports Amyloid Hypothesis
- Profilin Gene Is Actin’ in ALS
- Experimental α7 Agonist Meets Cognitive and Clinical Endpoints
- No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers
- When Is a C9ORF72 Repeat Expansion Not a C9ORF72 Repeat Expansion?
- Wave of New BACE Inhibitors Heading to Phase 2
- CSF Markers: Goodbye, Research Use Only; Hello, Clinical
- Me, Too: Florbetaben, Flutemetamol Look Good in Trial
- Soluble Aβ Takes Blame for Hyperactive Neurons in Mouse Brain
- Synaptic Plasticity Falters Early in AD Mice
- Collaborative Umbrella CAPs Three Prevention Trial Initiatives
- Clinical Trials of Intravenous Bapineuzumab Halted
- iPSC Disease Models Up and Coming for AD, Down’s, ALS
- FTD Risk Factor Confirmed, Alters Progranulin Pathways
- Phase 3 Solanezumab Trials "Fail"—Is There a Silver Lining?
- New AlzRisk Analysis: Brain Injury Promotes Dementia, But Is It AD?
- Who Will Pay for New Amyloid Scans? The Lobbying Has Begun
- Bapineuzumab Phase 3: Target Engagement, But No Benefit
- Dementia Four Times More Likely in Pro Football Players
- ENCODE Turns Human Genome From Sequence to Machine
- Newly Mapped DNA Elements Help Interpret GWAS
- C9ORF72 Steals the Show at Frontotemporal Dementia Meeting
- Will Tau Drug Show Its True Colors in Phase 3 Trials?
- The Solanezumab Benefit: Oh, So Small, But Probably Real
- DIAN Trial Picks Gantenerumab, Solanezumab, Maybe BACE Inhibitor
- Mutations in TREM2 Cause Frontotemporal Dementia
- ApoE4 Promotes Aβ Oligomerization
- Ironing Out Apoptotic Role for New APP-Binding Protein
- CTAD: New Data on Sola, Bapi, Spark Theragnostics Debate
- CTAD: Regulatory Science Gains Prominence in AD Research
- CTAD: Adaptive Antibody Trial to Try Bayesian Statistics
- Biomarker Progress? Picking the New, Better Measuring the Old
- CTAD: EEG Gains Luster as More Trials Incorporate Biomarkers
- Meet the New Progressive Tauopathy: CTE in Athletes, Soldiers
- Boxing: Study of Human Model for CTE Enters Second Round
- Soothing Neuroinflammation Quells Plaques in Mice
- SfN: Tau Toxicity in the Limelight
- Merck Launches Largest Trial of BACE Inhibitor in AD
- Could β-Arrestin Provide New Way to Halt Aβ Accumulation?
- Solanezumab Heads for New Phase 3 Trial
- Insurance Coverage of AD Diagnostics? Not Without Better Data
- To Reveal or Not to Reveal? New Data on the Question
- Expanding the Network, DIAN Starts Showing Longitudinal Data
- Thousands of Whole Genomes to Be Mined for New Clues to AD
- API Echoes DIAN: Biomarker Changes Precede Symptoms by 20 Years
- Enter the New Alzheimer’s Gene: TREM2 Variant Triples Risk
- Toxic Synuclein Corrupts Native in Wild-Type Mice
- Déjà Vu? AD Patients Again Look Worse on γ-Secretase Inhibitor
- CTE Advocates Pivot Toward Preventing Concussions in Kids
- Drug Company Halts Development of γ-Secretase Inhibitor Avagacestat
- Natural History-Cum-Trials Initiative, Grants to Boost Down’s Research
- Does ApoE4 Lower Brain Metabolism Independently of Aβ?
- Microglia and AD—Does the Inflammasome Drive Aβ Pathology?